Computer software, to run partly as a Cloud computing service and partly on local devices, using new, patented forms of machine learning and artificial intelligence to achieve personalised organ-scale medicine in a way that has been previously impossible.
In other words, we’re using advanced mathematics to achieve personalised medicine for complex diseases, partly by data-mining medical histories in a completely new way. This is achieved without waiting for genetics-based therapies and in a way that cannot be replaced by genetics-based therapies.
Already validated in silico (i.e. using computer simulations) and by data-mining actual medical histories, this software is most relevant for enhancing medication in chronic or degenerative diseases: our immediate application is enhanced insulin dosing for type-1 diabetes. The objective is to improve both quality of life and therapeutic outcomes for patients, particularly those suffering from highly unstable forms of type-1 diabetes.
